Literature DB >> 22346252

Survival analysis of cholangiocarcinoma: a 10-year experience in Malaysia.

Ahmad Ramzi Yusoff1, Mohd Muzammil Abdul Razak, Boon Koon Yoong, R Vijeyasingam, Zuraidah Mahmud Siti.   

Abstract

AIM: To investigate the clinical features and survival of patients treated for cholangiocarcinoma in our institution and to analyze the factors affecting their survival.
METHODS: This retrospective cohort study assessed patients diagnosed with cholangiocarcinoma between January 1997 and December 2007 at the University Malaya Medical Centre in Malaysia. The clinical data and associated outcomes were collected using a structured proforma.
RESULTS: Of the 69 patients diagnosed with cholangiocarcinoma, 38 (55%) were male; mean patient age was 61 years. Twelve patients (17%) had intrahepatic, 38 (55%) had perihilar and 19 (28%) had distal tumors. Only 12 patients underwent curative surgery, including seven R0 resections. Only one patient died within 30 d after surgery. The overall median survival was 4 mo, whereas the median survival of R0 resected patients was 16 mo. The overall 1-, 2- and 3-year cumulative survival rates were 67%, 17% and 17%, respectively. Survival rates were significantly associated with curative resection (P = 0.002), intrahepatic tumor (P = 0.003), negative margin status (P = 0.013), early tumor stage (P = 0.016), higher tumor differentiation (P = 0.032) and absence of jaundice (P = 0.038). Multivariate analysis showed that tumor location was a significant independent predictor of patient survival.
CONCLUSION: Curative, margin-negative resection of early stage, well-differentiated intrahepatic tumors is associated with improved patient survival.

Entities:  

Keywords:  Bile duct tumor; Cholangiocarcinoma; Malaysia; Surgery

Mesh:

Year:  2012        PMID: 22346252      PMCID: PMC3270511          DOI: 10.3748/wjg.v18.i5.458

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy.

Authors:  F Donato; U Gelatti; A Tagger; M Favret; M L Ribero; F Callea; C Martelli; A Savio; P Trevisi; G Nardi
Journal:  Cancer Causes Control       Date:  2001-12       Impact factor: 2.506

2.  Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document.

Authors:  S A Khan; B R Davidson; R Goldin; S P Pereira; W M C Rosenberg; S D Taylor-Robinson; A V Thillainayagam; H C Thomas; M R Thursz; H Wasan
Journal:  Gut       Date:  2002-11       Impact factor: 23.059

3.  Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma.

Authors:  D M Parkin; P Srivatanakul; M Khlat; D Chenvidhya; P Chotiwan; S Insiripong; K A L'Abbé; C P Wild
Journal:  Int J Cancer       Date:  1991-05-30       Impact factor: 7.396

4.  Clinicopathologic studies on perineural invasion of bile duct carcinoma.

Authors:  M R Bhuiya; Y Nimura; J Kamiya; S Kondo; S Fukata; N Hayakawa; S Shionoya
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

5.  Successful photodynamic therapy for nonresectable cholangiocarcinoma: a randomized prospective study.

Authors:  Marianne E J Ortner; Karel Caca; Frieder Berr; Jochen Liebetruth; Ulrich Mansmann; Dominik Huster; Winfried Voderholzer; Guido Schachschal; Joachim Mössner; Herbert Lochs
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

Review 6.  Endoscopic management of cholangiocarcinoma.

Authors:  Emad M Abu-Hamda; Todd H Baron
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

Review 7.  Photodynamic therapy for cholangiocarcinoma.

Authors:  Frieder Berr
Journal:  Semin Liver Dis       Date:  2004-05       Impact factor: 6.115

8.  A reappraisal of cholangiocarcinoma in patient with hepatolithiasis.

Authors:  M F Chen; Y Y Jan; C S Wang; T L Hwang; L B Jeng; S C Chen; T J Chen
Journal:  Cancer       Date:  1993-04-15       Impact factor: 6.860

Review 9.  Diagnosis and treatment of cholangiocarcinoma.

Authors:  Christopher D Anderson; C Wright Pinson; Jordan Berlin; Ravi S Chari
Journal:  Oncologist       Date:  2004

Review 10.  A review and update on cholangiocarcinoma.

Authors:  Matthew J Olnes; Rodrigo Erlich
Journal:  Oncology       Date:  2004       Impact factor: 2.935

View more
  10 in total

1.  Utilizing signature-score to identify oncogenic pathways of cholangiocarcinoma.

Authors:  Tzu-Hung Hsiao; Hung-I Harry Chen; Jo-Yang Lu; Pei-Ying Lin; Charles Keller; Sarah Comerford; Gail E Tomlinson; Yidong Chen
Journal:  Transl Cancer Res       Date:  2013-02-01       Impact factor: 1.241

2.  Values of MRI Imaging Presentations in the Hepatobiliary Phase, DWI and T2WI Sequences in Predicting Pathological Grades of Intrahepatic Mass-Forming Cholangiocarcinoma.

Authors:  Li-Hong Xing; Li-Yong Zhuo; Jia-Ning Wang; Yan Zhang; Feng-Ying Zhu; Chu Wang; Xiao-Ping Yin; Bu-Lang Gao
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

3.  Prognostic factors in resectable cholangiocarcinoma patients: Carcinoembryonic antigen, lymph node, surgical margin and chemotherapy.

Authors:  Kosin Wirasorn; Thundon Ngamprasertchai; Jarin Chindaprasirt; Aumkhae Sookprasert; Narong Khantikaew; Ake Pakkhem; Piti Ungarereevittaya
Journal:  World J Gastrointest Oncol       Date:  2013-04-15

4.  Cohort profile: cholangiocarcinoma screening and care program (CASCAP).

Authors:  Narong Khuntikeo; Nittaya Chamadol; Puangrat Yongvanit; Watcharin Loilome; Nisana Namwat; Paiboon Sithithaworn; Ross H Andrews; Trevor N Petney; Supannee Promthet; Kavin Thinkhamrop; Chaiwat Tawarungruang; Bandit Thinkhamrop
Journal:  BMC Cancer       Date:  2015-06-09       Impact factor: 4.430

5.  Differentiating peripheral cholangiocarcinoma in stages T1N0M0 and T2N0M0 from hepatic hypovascular nodules using dynamic contrast-enhanced MRI.

Authors:  Shihong Li; Haizhen Qian; Yu Peng; Huihui Jia; Guangwu Lin
Journal:  Sci Rep       Date:  2017-08-14       Impact factor: 4.379

6.  Genomic architecture of FGFR2 fusions in cholangiocarcinoma and its implication for molecular testing.

Authors:  Olaf Neumann; Timothy C Burn; Michael Allgäuer; Markus Ball; Martina Kirchner; Thomas Albrecht; Anna-Lena Volckmar; Susanne Beck; Volker Endris; Hannah Goldschmid; Ulrich Lehmann; Huriye Seker-Cin; Sebastian Uhrig; Stephanie Roessler; Jan Budczies; Stefan Fröhling; Thomas Longerich; Alex H Wagner; Arndt Vogel; Peter Schirmacher; Albrecht Stenzinger; Daniel Kazdal
Journal:  Br J Cancer       Date:  2022-07-23       Impact factor: 9.075

7.  Functional and genetic characterization of three cell lines derived from a single tumor of an Opisthorchis viverrini-associated cholangiocarcinoma patient.

Authors:  Banchob Sripa; Wunchana Seubwai; Kulthida Vaeteewoottacharn; Kanlayanee Sawanyawisuth; Atit Silsirivanit; Worasak Kaewkong; Kanha Muisuk; Paweena Dana; Chatchai Phoomak; Worachart Lert-Itthiporn; Vor Luvira; Chawalit Pairojkul; Bin T Teh; Sopit Wongkham; Seiji Okada; Yaovalux Chamgramol
Journal:  Hum Cell       Date:  2020-03-23       Impact factor: 4.174

8.  Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area.

Authors:  Prakongboon Sungkasubun; Surachate Siripongsakun; Kunlayanee Akkarachinorate; Sirachat Vidhyarkorn; Akeanong Worakitsitisatorn; Thaniya Sricharunrat; Sutida Singharuksa; Rawisak Chanwat; Chairat Bunchaliew; Sirima Charoenphattharaphesat; Ruechuta Molek; Maneenop Yimyaem; Gaidganok Sornsamdang; Kamonwan Soonklang; Kasiruck Wittayasak; Chirayu U Auewarakul; Chulabhorn Mahidol
Journal:  BMC Cancer       Date:  2016-06-02       Impact factor: 4.430

9.  Health-Related Quality of Life and Survival of Cholangiocarcinoma Patients in Northeastern Region of Thailand.

Authors:  Somkiattiyos Woradet; Nopparat Songserm; Supannee Promthet; Donald Maxwell Parkin
Journal:  PLoS One       Date:  2016-09-29       Impact factor: 3.240

10.  Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma.

Authors:  Elena V Poddubskaya; Madina P Baranova; Daria O Allina; Philipp Y Smirnov; Eugene A Albert; Alexey P Kirilchev; Alexey A Aleshin; Marina I Sekacheva; Maria V Suntsova
Journal:  Exp Hematol Oncol       Date:  2018-09-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.